Appointed
Joseph M. Manko Jr.
Class I director
MYO ·
MYOMO, INC.
the Board appointed Joseph M. Manko Jr. to join the Board, effective on May 9, 2026.
Ready 8-Ks
22
Latest filing
May 13, 2026, 4:10 PM ET
Top materiality
0.85
Event mix
earnings ×10 · other_material ×6 · leadership ×2
Sentiment
10 pos · 2 neg · 10 neu
Latest earnings
▲ beat 2026-Q1
Executive change
recent →
Recent 8-K filings for MYO
Highest-materiality recent filing
Myomo Q2 revenue $9.7M (+28%) but operating loss widens; cuts FY2025 guidance to $40-42M
- Revenue $9.7M (+28% YoY), revenue units 178 (+13%), ASP ~$54,200 (+14%).
- Orders/authorizations 207 (-3%), backlog 230 units (-18%), pipeline adds 816 (+49%).
-
Myomo appoints Joseph Manko Jr., founder of Horton Capital, as director
Joseph M. Manko Jr. appointed as Class I director effective May 9, 2026, through 2027 annual meeting.
-
Myomo Q1 revenue $10.1M (+3% YoY); net loss narrows to $3.0M; guides Q2 $10.3M-$10.8M
Revenue $10.1M (+3% YoY), net loss $3.0M ($0.07/sh) vs $3.5M loss ($0.08/sh) in Q1 2025.
-
Myomo appoints William J. Febbo to Board, effective April 14, 2026
Febbo, 57, is CEO of Performance Health Systems and former CEO of OptimizeRx (OPRX), where he grew revenue from $5M to $92M.
-
Myomo Q4 revenue falls 6% to $11.4M; net loss widens to $3.8M
Q4 revenue $11.4M (-6% YoY); full year $40.9M (+26% YoY).
-
Myomo CEO & CFO take 10% salary cut in 2026, receiving RSUs at 115% of foregone amount
CEO Paul Gudonis voluntarily reduces 2026 base salary 10% ($40,000) for RSUs worth $46,000 (115% of foregone).
-
Myomo Q3 revenue $10.1M (+10% YoY); net loss $0.09/shr; FY guidance $40-42M
Revenue $10.1M, up 10% YoY; 186 units sold (+16%), ASP ~$54,200 (-5%).
-
Myomo Q2 revenue $9.7M (+28%) but operating loss widens; cuts FY2025 guidance to $40-42M
Revenue $9.7M (+28% YoY), revenue units 178 (+13%), ASP ~$54,200 (+14%).
-
Myomo sets 2028 revenue target of $100M, gross margin 70-72% at Investor Day
Aspirational goal of $100M annual revenue by 2028, including $15M international and $20M O&P channel revenue.
-
Myomo stockholders elect Heather Getz as Class II director, ratify CBIZ as auditor for FY2025
Heather Getz elected as Class II director for three-year term expiring at 2028 annual meeting; 10,294,384 for, 1,888,001 withheld, 12,131,966 broker non-votes.
-
Myomo Q1 revenue $9.8M (+162%); record 700 pipeline adds; guides Q2 $9.0-9.5M
Revenue $9.8M (+162% YoY) on 182 units (+100%); gross margin 67.2% (up 600 bps).
-
Myomo names CBIZ as new auditor; two directors exit board
Marcum LLP resigned as auditor April 8; CBIZ CPAs engaged after acquiring Marcum's attest business.
-
Myomo Q4 revenue $12.1M record, first positive op. cash flow; guides FY2025 $50-53M
Q4 revenue $12.1M (+154% YoY); 220 units shipped (+106%); ASP ~$54,900 (+23%).
-
Myomo enters $3M term loan with SVB; revises revolver Medicare concentration limit
New $3M term loan available until Feb 28, 2026; repayable in 36 monthly installments from Mar 1, 2026, maturing Feb 1, 2029.
-
Myomo prices $15M public offering of 3M shares at $5.00; underwriter option exercised in full
3,000,000 shares priced at $5.00 each; gross proceeds of $15.0M expected before expenses.
-
Myomo Q3 revenue record $9.2M (+81% YoY); FY guidance raised to $30-31M
Record Q3 product revenue $9.2M, +83% YoY; net loss $1.0M ($0.03/sh) vs $2.0M loss year ago.
-
Myomo signs 88-month lease for 36,208 sq ft in Burlington, MA for HQ and manufacturing
Lease for approx. 36,208 rentable sq ft at 45 Blue Sky Drive; monthly rent starts at $96,250 and escalates over 8-year term.
-
Myomo Q2 2024 revenue $7.5M (+77% product revenue); record 213 MyoPro orders
Product revenue $7.5M (+77% YoY); total revenue $7.5M (+26% YoY) reflecting prior-year license fee.
-
Myomo enters $4M revolving credit facility with Silicon Valley Bank
Revolver up to $4M (expandable to $5.5M); interest rate greater of 8.50% or prime + 0.50%.
-
Myomo expects record Q2 revenue $7.2M-$7.4M, up 92-97% sequentially
Preliminary Q2 revenue $7.2M-$7.4M, 92-97% sequential increase, highest ever.
-
Myomo shareholders elect Crowley and Morris as Class I directors, ratify Marcum as auditor
Thomas A. Crowley received 9,246,482 votes for, 1,049,041 withheld, and 11,747,021 broker non-votes.
-
Myomo Q1 revenue $3.8M (+9% YoY); backlog record 275 units; net loss $3.8M
Revenue $3.8M (+9% YoY); product revenue $3.75M; revenue units 91 (+14%).
-
Myomo receives first lump sum Medicare reimbursements for MyoPro under new CMS fees
CMS through DME MACs remitted lump sum reimbursements for MyoPros to Medicare Part B beneficiaries.
Executive changes
Departed
Yitzchak Jacobovitz
Director
MYO ·
MYOMO, INC.
Also on April 4, 2025, Mr. Yitzchak Jacobovitz, a member of the Board and the Nominating and Corporate Governance Committee of the Board, informed the Company that he does not intend to stand for reelection at the Annual Meeting.
Departed
Amy Knapp
Director
MYO ·
MYOMO, INC.
On April 4, 2025, Ms. Amy Knapp, a member of the Board, the Audit Committee of the Board and the Nominating and Corporate Governance Committee of the Board, informed the Company that she does not intend to stand for reelection at the Company’s 2025 annual meeting of shareholders
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.70 · Most common event earnings